Overview

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Status:
NOT_YET_RECRUITING

Trial end date:
2026-11-22

Target enrollment:

Participant gender:

Summary

To explore and evaluate the safety and efficacy of camrelizumab combined with chemotherapy ± thalidomide in first-line treatment of advanced non-small cell lung cancer patients

Phase:

PHASE4

Details

Lead Sponsor:

Tongji University

Collaborator:

Shanghai Pulmonary Hospital, Shanghai, China

Treatments:

camrelizumab